Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Nuvectis Pharma and Sunshine Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvectis Pharma | N/A | -155.80% | -104.02% |
| Sunshine Biopharma | -12.82% | -17.89% | -14.25% |
Valuation and Earnings
This table compares Nuvectis Pharma and Sunshine Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvectis Pharma | N/A | N/A | -$22.26 million | ($1.11) | -7.52 |
| Sunshine Biopharma | $32.96 million | 0.07 | -$4.51 million | ($150.88) | -0.01 |
Risk & Volatility
Nuvectis Pharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Nuvectis Pharma and Sunshine Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvectis Pharma | 0 | 0 | 1 | 0 | 3.00 |
| Sunshine Biopharma | 0 | 0 | 1 | 0 | 3.00 |
Nuvectis Pharma presently has a consensus target price of $11.00, suggesting a potential upside of 31.74%. Sunshine Biopharma has a consensus target price of $15.00, suggesting a potential upside of 685.34%. Given Sunshine Biopharma’s higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Nuvectis Pharma.
Institutional and Insider Ownership
96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 35.8% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 0.1% of Sunshine Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Sunshine Biopharma beats Nuvectis Pharma on 7 of the 11 factors compared between the two stocks.
About Nuvectis Pharma
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
